Drugs Containing Excipient (Inactive Ingredient) .ALPHA.-TOCOPHEROL ACETATE

Branded drugs containing .ALPHA.-TOCOPHEROL ACETATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Quality Care Products LLC	BELBUCA	buprenorphine hydrochloride	55700-867	.ALPHA.-TOCOPHEROL ACETATE
BioDelivery Sciences International Inc	BUNAVAIL	buprenorphine and naloxone	59385-012	.ALPHA.-TOCOPHEROL ACETATE
BioDelivery Sciences International Inc	BELBUCA	buprenorphine hydrochloride	59385-021	.ALPHA.-TOCOPHEROL ACETATE

Generic drugs containing .ALPHA.-TOCOPHEROL ACETATE excipient

Company	Ingredient	NDC	Excipient
Alvogen Inc	buprenorphine buccal	47781-471	.ALPHA.-TOCOPHEROL ACETATE
Quality Care Products LLC	buprenorphine hydrochloride	55700-867	.ALPHA.-TOCOPHEROL ACETATE
BioDelivery Sciences International Inc	buprenorphine and naloxone	59385-012	.ALPHA.-TOCOPHEROL ACETATE
BioDelivery Sciences International Inc	buprenorphine hydrochloride	59385-021	.ALPHA.-TOCOPHEROL ACETATE
Zydus Pharmaceuticals USA Inc	sirolimus	68382-351	.ALPHA.-TOCOPHEROL ACETATE

Alpha-Tocopherol Acetate Market Dynamics and Financial Trajectory

Last updated: August 8, 2026

Alpha-tocopherol acetate, also called vitamin E acetate, is a mature, globally traded excipient and active vitamin ingredient. Its pharmaceutical economics are driven by formulation demand, vitamin supplementation, dermatology, cosmetics, animal nutrition, and food applications rather than by a single branded medicine. The compound has low patent barriers, multiple manufacturing sources, and strong substitution pressure from other tocopherol forms. Public companies generally report it within broader vitamin, nutrition, specialty chemicals, or excipient portfolios, so standalone revenue and margin data are limited.

What is alpha-tocopherol acetate used for in pharmaceuticals?

Alpha-tocopherol acetate is a stabilized ester of alpha-tocopherol. The acetate form is less susceptible to oxidation than free tocopherol and is used where formulation stability and shelf life matter.

Attribute	Data
Common names	Alpha-tocopherol acetate; vitamin E acetate; all-rac-alpha-tocopheryl acetate
CAS number	7695-91-2
Molecular formula	C31H52O3
Molecular weight	472.74 g/mol
Physical form	Oily liquid or semi-solid, depending on grade and temperature
Main pharmaceutical role	Vitamin active ingredient, antioxidant, lipid-phase excipient, skin-conditioning ingredient
Common dosage forms	Softgels, capsules, oral liquids, topical creams, ointments, emulsions
Key standards	USP-NF, Ph. Eur., BP and other national pharmacopeial specifications
Commercial source types	Synthetic all-racemic material and natural-source vitamin E derivatives

In oral pharmaceutical products, alpha-tocopherol acetate is most often the vitamin E active rather than a conventional inactive excipient. It can also function as an antioxidant or oil-phase stabilizer in formulations, but its principal commercial value comes from its nutritional and therapeutic vitamin activity.

The acetate group is hydrolyzed after administration to release alpha-tocopherol. The compound is commonly selected over free alpha-tocopherol because it is easier to handle in oxygen-sensitive formulations.

What drives demand for alpha-tocopherol acetate?

Demand is diversified across pharmaceutical, nutraceutical, food, cosmetic and animal-health markets. Pharmaceutical demand is important for quality requirements but is unlikely to represent the majority of global volume.

Pharmaceutical and nutraceutical demand

The main pharmaceutical uses include vitamin E supplements, prenatal and multivitamin products, products for vitamin E deficiency, and specialty nutrition formulations. Vitamin E acetate is also used in softgel systems because it is compatible with lipid carriers and can be filled at relatively high concentrations.

Nutraceutical demand is more volume-sensitive than prescription pharmaceutical demand. Retail vitamin sales, private-label supplements and contract manufacturing create purchasing opportunities for large-volume producers but increase price competition.

Cosmetics and dermatology

Cosmetic products use vitamin E acetate in creams, lotions, sunscreens, lip products and after-sun preparations. The acetate form is used for emollience, skin-conditioning claims and oxidative stability. Cosmetic demand broadens the customer base but subjects suppliers to lower average prices and frequent reformulation pressure.

Food and animal nutrition

Food fortification and animal-feed applications create additional demand for vitamin E derivatives. These markets are typically more exposed to commodity pricing, agricultural cycles, currency movements and feed demand than pharmaceutical supply contracts.

Regional demand

North America and Europe remain high-value markets because of pharmacopeial, quality and documentation requirements. Asia-Pacific is the largest strategic growth region because of its manufacturing base, supplement consumption, pharmaceutical production and expanding middle-class demand. China is important both as a producer and a consumer. India is a significant pharmaceutical formulation and generic-drug manufacturing center.

How large is the alpha-tocopherol acetate market?

No authoritative public source reports a standalone global market size, revenue pool or profit margin for pharmaceutical-grade alpha-tocopherol acetate. Market research estimates often combine vitamin E acetate with other vitamin E forms or group the material within the broader vitamin E market.

The relevant commercial market should be analyzed in layers:

Market layer	Commercial characteristic	Likely pricing profile
Pharmaceutical-grade alpha-tocopherol acetate	Highest documentation and testing burden	Premium to technical grade
Nutraceutical grade	Large volume, strong private-label demand	Competitive
Food grade	High volume and specification-driven	Competitive
Cosmetic grade	Formulation and sensory requirements	Moderate
Animal-nutrition grade	Large-volume purchasing	Price-sensitive
Specialty delivery systems	Emulsion, water-dispersible or encapsulated forms	Higher value per kilogram

The market is mature rather than discovery-driven. Volume growth is likely to track population, supplement penetration, pharmaceutical production, cosmetic consumption and regional income growth. Price growth depends more on feedstock costs, plant utilization, regulatory compliance and supply concentration than on new clinical demand.

What is the financial trajectory for alpha-tocopherol acetate?

The financial trajectory is best characterized as a mature, cyclical and margin-sensitive ingredient market.

Revenue trajectory

Revenue growth has four main components:

1. Unit-volume growth from supplements, pharmaceutical formulations and cosmetics.
2. Price changes linked to raw materials and manufacturing capacity.
3. Product-mix changes between commodity and high-specification grades.
4. Geographic expansion, especially in Asia-Pacific and emerging markets.

A supplier with a broad vitamin portfolio can increase revenue during periods of higher vitamin E prices even when underlying volumes are flat. The reverse also applies: declining prices can reduce reported revenue without a comparable reduction in kilograms sold.

Margin trajectory

Gross margins are exposed to:

• Aromatic and petrochemical feedstocks used in synthetic production.
• Energy and solvent costs.
• Plant utilization.
• Batch size and purification requirements.
• Quality-control testing.
• Regulatory documentation.
• Freight and inventory costs.
• Customer concentration.

Pharmaceutical-grade product can command a premium because customers require traceability, validated manufacturing, impurity controls, stability data and change-control support. The premium is limited by the availability of technically interchangeable suppliers.

Cash-flow profile

The product generally has favorable working-capital characteristics when sold under recurring supply agreements. The principal risks are inventory revaluation, long customer qualification cycles, raw-material purchases ahead of demand and price pressure from distributors.

Large pharmaceutical customers may impose lengthy qualification and audit requirements. Once approved, a supplier can retain business through documentation quality and change-management performance, even when its price is not the lowest.

Which companies supply alpha-tocopherol acetate?

The supply chain includes integrated vitamin manufacturers, specialty ingredient companies, chemical producers, distributors and contract manufacturers. Publicly visible suppliers and relevant market participants include:

• dsm-firmenich, through its vitamin and nutrition activities.
• BASF, through its human and animal nutrition portfolio.
• Zhejiang Medicine and related Chinese vitamin producers.
• NHU and other Chinese vitamin manufacturers.
• BTSA and other specialty vitamin E producers.
• Specialty distributors supplying USP, Ph. Eur. and cosmetic grades.
• Contract manufacturers that purchase bulk material and fill softgels or formulate finished products.

Supplier participation varies by grade. A company active in technical or feed-grade vitamin E may not qualify as a pharmaceutical-grade source. The commercial distinction depends on the manufacturing site, quality system, analytical package and customer approvals, not only on the chemical identity.

Competitive structure

The market has a mixed structure:

• Large integrated suppliers have scale, procurement leverage and broad regulatory infrastructure.
• Chinese producers can exert strong price pressure in commodity and intermediate grades.
• Specialty suppliers compete through documentation, custom concentrations, water-dispersible systems and technical support.
• Distributors compete through inventory, regional access and regulatory services.

The main competitive advantage is supply reliability rather than proprietary chemistry. Qualification status can be more valuable than nominal manufacturing cost for regulated pharmaceutical customers.

What formulations are protected by alpha-tocopherol acetate patents?

Alpha-tocopherol acetate itself is a long-established compound and is not commercially protected by a meaningful composition-of-matter patent. The relevant intellectual-property opportunities generally involve formulations, delivery systems, combinations or manufacturing processes.

Potentially protectable areas include:

• Water-dispersible vitamin E acetate compositions.
• Self-emulsifying oral delivery systems.
• Softgel formulations with improved content uniformity.
• Topical emulsions with enhanced stability or skin penetration.
• Combination products containing vitamin E and other vitamins, minerals or active ingredients.
• Controlled-release or targeted delivery systems.
• Purification methods and impurity-control processes.
• Microencapsulation and spray-dried powders.
• Specific pharmaceutical uses in deficiency states or disease-support formulations.

A patent covering a formulation would usually protect the specified composition and process, not the entire market for alpha-tocopherol acetate. Freedom-to-operate analysis therefore requires review of claims directed to excipient ratios, dosage forms, particle characteristics, manufacturing conditions and therapeutic combinations.

When does alpha-tocopherol acetate lose exclusivity?

The core compound has no practical remaining exclusivity period. Alpha-tocopherol acetate is a mature generic chemical available from multiple global sources.

Exclusivity category	Status
Composition-of-matter exclusivity	Expired or commercially irrelevant
Standalone regulatory exclusivity	None identified for the ingredient
Generic supplier access	Broad
Formulation patent risk	Product-specific and claim-dependent
Method-of-use patent risk	Limited to narrow therapeutic claims
Manufacturing patent risk	Possible for specialized processes
Trade-secret risk	Relevant to yield, purification and impurity control

A finished pharmaceutical product containing alpha-tocopherol acetate may still have patent or regulatory exclusivity. That protection would belong to the product’s formulation, combination, delivery system or approved use, not to the basic vitamin E acetate molecule.

What is the FDA regulatory status of alpha-tocopherol acetate?

The FDA recognizes alpha-tocopherol acetate as an established ingredient used in drug and dietary-product contexts. The FDA Inactive Ingredient Database includes excipient information for approved drug products, but the database should be interpreted by route, dosage form and maximum potency rather than as a universal approval for every formulation.[1]

Relevant regulatory considerations include:

• Identity and assay testing.
• Residual solvents and elemental impurities.
• Peroxide and oxidative degradation controls.
• Microbial quality for applicable dosage forms.
• Stability under light, heat and oxygen exposure.
• Source and stereochemical designation.
• Compliance with applicable USP-NF or other pharmacopeial monographs.
• Documentation of manufacturing-site changes.
• Excipient suitability for the proposed route and dose.

For a new drug application, the sponsor must establish that the grade, concentration and route are suitable for the proposed formulation. Prior use in approved products can support development but does not eliminate product-specific review.

Is vitamin E acetate approved for inhalation use?

The 2019 outbreak of e-cigarette, or vaping, product use-associated lung injury linked vitamin E acetate to serious respiratory harm when the substance was used in illicit or nonstandard vaping products.[2] That public-health finding does not establish a general pharmaceutical inhalation approval for alpha-tocopherol acetate.

Inhalation use presents a materially different risk profile from oral, topical or softgel use. A company should not treat oral or topical excipient precedent as evidence of inhalation suitability.

Does alpha-tocopherol acetate have Orange Book listings?

Alpha-tocopherol acetate is not an Orange Book-protected active ingredient in the manner of a currently patented branded drug. The FDA Orange Book lists approved drug products and patent information submitted by sponsors; it does not function as a comprehensive database of excipient patents.[3]

An approved finished product containing vitamin E acetate could have a listing if the sponsor submitted an applicable formulation or method-of-use patent. Such a listing would be tied to that product and patent claims. It would not create ingredient-level exclusivity for all alpha-tocopherol acetate products.

Are there Paragraph IV challenges involving alpha-tocopherol acetate?

There is no broad Paragraph IV litigation pattern associated with alpha-tocopherol acetate as a standalone ingredient. Paragraph IV litigation generally arises when an abbreviated new drug application applicant challenges patents listed for a branded finished drug. A generic vitamin E acetate product would ordinarily face formulation-specific or product-specific patents rather than a basic compound patent.

The practical litigation risks are:

• A patent listed for a branded combination product.
• A softgel or delivery-system patent.
• A method-of-use patent.
• A patent covering a specific concentration or formulation.
• Trade-secret claims involving manufacturing technology.
• Contract disputes involving supply, specifications or change control.

The basic molecule is unlikely to support a high-value patent dispute by itself.

What manufacturing and intellectual-property barriers affect supply?

Manufacturing barriers are operational rather than exclusionary.

Manufacturing barriers

Producers must control:

• Oxidation and degradation.
• Isomeric composition.
• Residual solvents.
• Catalyst residues.
• Color and odor.
• Assay and potency.
• Batch-to-batch consistency.
• Packaging oxygen permeability.
• Stability during transport and storage.

Pharmaceutical customers can require audit access, validated analytical methods, stability commitments and notification periods for manufacturing changes. These requirements can delay supplier substitution even when alternative producers exist.

Intellectual-property barriers

The strongest IP positions are likely to involve:

• High-purity production processes.
• Low-impurity synthetic routes.
• Improved crystallization or purification.
• Water-soluble or self-emulsifying derivatives.
• Encapsulation systems.
• Combination products with clinical or formulation advantages.

Trade secrets may have greater practical value than patents where process improvements are difficult to detect from the final product.

How does alpha-tocopherol acetate compare with other vitamin E forms?

Vitamin E form	Main advantage	Main limitation	Commercial positioning
Alpha-tocopherol acetate	Stability and broad formulation utility	Requires hydrolysis to release free tocopherol	Standard pharmaceutical and supplement form
Free alpha-tocopherol	Direct active form	More oxidation-sensitive	Specialty formulations
Mixed tocopherols	Broad antioxidant profile	Lower alpha-tocopherol specificity	Food, supplement and antioxidant applications
Natural d-alpha-tocopherol acetate	Higher natural-source positioning	Higher cost and source variability	Premium supplements and cosmetics
Synthetic dl-alpha-tocopherol acetate	Scalable and lower cost	Racemic composition	Mass-market pharmaceutical and nutrition use
Water-dispersible vitamin E	Improved aqueous formulation behavior	Higher processing cost	Liquid, beverage and specialty delivery systems

The principal substitution decision is between cost, stability, bioavailability positioning, source labeling and formulation performance. Synthetic all-racemic material is generally best positioned for cost-sensitive products. Natural-source material can capture a premium where consumers or formulators value natural origin.

What generic entry risks exist for alpha-tocopherol acetate products?

Generic entry risk is high at the ingredient level because:

• The molecule is mature.
• Multiple suppliers operate internationally.
• No meaningful molecule patent blocks supply.
• Regulatory precedents exist.
• Manufacturing technology is established.
• Customers can qualify alternative sources over time.

Risk is lower for specialized finished products where the manufacturer has:

• A difficult-to-replicate delivery system.
• A narrow approved use.
• A strong formulation patent.
• Clinical data supporting a specific dose or combination.
• Long-term customer qualification records.
• A proprietary softgel or emulsion platform.

For an incumbent supplier, the main defense is operational execution, quality consistency, regulatory support and customer integration.

What licensing deals and litigation affect the market?

No major licensing transaction or widely reported patent settlement appears to define the standalone alpha-tocopherol acetate market. Commercial agreements are more likely to involve:

• Distribution rights.
• Private-label vitamin products.
• Contract manufacturing.
• Regional supply arrangements.
• Natural-source material procurement.
• Finished-dose softgel production.
• Formulation technology.

The absence of a major public settlement is consistent with a mature ingredient market where competition centers on supply, price and qualification rather than exclusionary patent rights.

What is the investment outlook for alpha-tocopherol acetate?

Alpha-tocopherol acetate is more attractive as part of a diversified vitamin, nutrition or specialty-ingredient platform than as a standalone growth asset.

Positive financial factors

• Broad end-market exposure.
• Recurring demand from supplements and pharmaceutical products.
• Established manufacturing technology.
• Low clinical-development risk.
• Potential premiums for pharmaceutical and natural-source grades.
• Opportunities in water-dispersible and encapsulated delivery systems.

Negative financial factors

• Commodity-like pricing in standard grades.
• Limited molecule-level IP.
• Supplier substitution.
• Exposure to Chinese capacity and global oversupply.
• Raw-material and energy volatility.
• Weak standalone revenue visibility.
• Regulatory risk for nonstandard routes, particularly inhalation.

Base-case trajectory

The most defensible base case is low-to-moderate volume growth, periodic price volatility and stable-to-compressed margins for standard material. Higher returns should come from differentiated delivery systems, pharmaceutical-grade documentation, natural-source products and integrated customer relationships rather than from the core molecule.

Key Takeaways

• Alpha-tocopherol acetate is a mature vitamin E ingredient with pharmaceutical, nutraceutical, cosmetic, food and animal-health demand.
• Its primary pharmaceutical value is as a stabilized vitamin E active; excipient use is secondary.
• No standalone public market figure reliably isolates pharmaceutical-grade alpha-tocopherol acetate revenue.
• The compound has no meaningful remaining composition-of-matter exclusivity.
• Generic and supplier-entry risk is high for the basic ingredient.
• Formulation, delivery-system, process and method-of-use patents can protect specific products.
• FDA suitability depends on route, dosage form, concentration, quality and prior-use evidence.
• Oral, topical and softgel use should not be extrapolated to inhalation products.
• The market’s financial trajectory is mature, cyclical and margin-sensitive.
• Commercial value is highest in differentiated grades, reliable supply, regulatory support and proprietary delivery systems.

FAQs

Is alpha-tocopherol acetate the same as vitamin E?

Yes. Alpha-tocopherol acetate is an esterified form of vitamin E commonly used for improved stability in supplements, pharmaceuticals and cosmetics.

Is alpha-tocopherol acetate a pharmaceutical excipient or an active ingredient?

It can be either. In vitamin products it is generally the active ingredient. In other formulations it can act as an antioxidant, oil-phase stabilizer or skin-conditioning excipient.

Can alpha-tocopherol acetate be replaced by tocopherol?

Replacement depends on the formulation. Free tocopherol may provide different oxidation behavior, potency, handling and stability, so substitution requires formulation and regulatory assessment.

Does natural vitamin E acetate have stronger patent protection?

No. Natural-source positioning can support premium pricing, but it does not create molecule-level patent exclusivity. Commercial differentiation generally depends on source certification, labeling and formulation claims.

Is alpha-tocopherol acetate suitable for injectable drugs?

Suitability is formulation-specific and cannot be inferred from oral or topical use. Injectable products require route-specific excipient justification, purity controls, sterility strategy and regulatory review.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. Centers for Disease Control and Prevention. (2020). Outbreak of lung injury associated with the use of e-cigarette, or vaping, products. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Alpha tocopheryl acetate monograph. Rockville, MD: United States Pharmacopeial Convention.

5. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Tocopheryl acetate monograph. Strasbourg, France: Council of Europe.